Get access

Sr, Mg cosubstituted HA porous macro-granules: Potentialities as resorbable bone filler with antiosteoporotic functions

Authors

  • Elena Landi,

    Corresponding author
    • CNR-ISTEC, National Research Council, Institute of Science and Technology for Ceramics, 48018 Faenza, Italy
    Search for more papers by this author
  • Jacopo Uggeri,

    1. Dipartimento di Scienze Biomediche, Biotecnologiche e Traslazionali, S.Bi.Bi.T, Unità di Anatomia, Istologia ed Embriologia, University of Parma, 43100 Parma, Italy
    Search for more papers by this author
  • Valentina Medri,

    1. CNR-ISTEC, National Research Council, Institute of Science and Technology for Ceramics, 48018 Faenza, Italy
    Search for more papers by this author
  • Stefano Guizzardi

    1. Dipartimento di Scienze Biomediche, Biotecnologiche e Traslazionali, S.Bi.Bi.T, Unità di Anatomia, Istologia ed Embriologia, University of Parma, 43100 Parma, Italy
    Search for more papers by this author

Correspondence to: E. Landi; e-mail: elena.landi@istec.cnr.it

Abstract

Porous macro-granules of nanostructured apatite with Ca ions partially cosubstituted with Mg and Sr ions in different ratios (SrMgHAs), were synthesized at 37°C and compared with Mg and/or Sr free apatites (MgHAs and HA). Strontium improved the Mg substitution extent in the apatite and the chemical-physical and thermal stability of the resulting cosubstituted apatite. Porous macro-granules of 400–600 micron with selected composition were tested for the ionic release in synthetic body fluid and the data were related with the results of preliminary cell investigation in vitro. As compared to the corresponding Sr-free granulate, the SrMgHA could be exploited to prolong the beneficial Mg release during the bone regeneration process. In addition the contemporary in situ supply of Sr, an antiosteoporotic and anticarie ion, could influence the quality of new hard tissues. The ionic multirelease created a more favorable environment for human osteoblasts, demonstrated by a proliferative effect for each dose tested in the range 0.1–10 mg/mL. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 101A: 2481–2490, 2013.

Ancillary